Wearable Injectors Market Size, Industry Trends, Growth & Forecast to 2033
The global wearable injectors market, valued at USD 10.14 billion in 2024, is projected to reach USD 42.72 billion by 2033, exhibiting a CAGR of 17.33% from 2025. This growth is driven by the increasing prevalence of chronic diseases, demand for self-administration of biologics, and advancements in smart technologies. Europe currently dominates the market, while North America is the fastest-growing region, with electromechanical wearable injectors and diabetes applications leading the respective segments.
West Pharmaceutical Services (WST) is Returning to Sustainable Volume Growth
Conestoga Capital Advisors highlighted West Pharmaceutical Services, Inc. (WST) in its Q4 2025 investor letter, noting the company's strong performance driven by its High-Value Products segment and GLP-1 therapies. Management indicated a moderation of destocking headwinds, signaling a return to sustainable volume growth for WST. While West Pharmaceutical Services is not among the 30 most popular stocks among hedge funds, Conestoga Capital Advisors believes it remains a critical partner to the pharmaceutical industry, poised to benefit from long-term trends toward biologic and injectable medicines.
Vanguard Group Inc. Buys 388,144 Shares of West Pharmaceutical Services, Inc. $WST
Vanguard Group Inc. increased its stake in West Pharmaceutical Services (NYSE: WST) by 4.2% in Q3, purchasing 388,144 shares and now owning 13.49% of the company, valued at approximately $2.546 billion. West Pharmaceutical Services reported strong quarterly earnings, beating analyst estimates with $2.04 EPS and $805 million in revenue, and announced a $1 billion share buyback program and a quarterly dividend. The company maintains a "Buy" rating from analysts with an average target price of $314.56.
Customer Concentration Risk: How Dependence on Key Accounts Threatens West Pharmaceutical’s Financial Stability
West Pharmaceutical Services, Inc. (WST) faces significant financial risk due to its high dependence on a small number of key customers. The loss of a major account or a reduction in orders could severely impact its business, financial condition, and operating results. This customer concentration also exposes the company to adverse contract terms and pricing pressures.
Assessing West Pharmaceutical Services (WST) Valuation After New US$1b Buyback And Earnings Update
West Pharmaceutical Services (WST) recently announced a new US$1 billion share buyback program and a regular US$0.22 quarterly dividend, following its 2025 earnings report. The stock's current price of around US$248 per share presents a mixed valuation picture, with one narrative suggesting it's 26.7% undervalued (fair value US$338.57) due to growth in GLP-1s and margin expansion, while a DCF model indicates it might be expensive with a fair value of US$103.01. Investors are encouraged to consider these contrasting views and perform their own analysis.
Pharmaceutical Packaging Market Trends and Growth
The global pharmaceutical packaging market is projected to grow from $126.2 billion in 2025 to $178.4 billion by 2030, at a CAGR of 7.2%. This growth is driven by technological advancements like smart packaging and specialized needs for biologics, as well as demand for child-resistant and senior-friendly designs. The report segments the market by material, packaging type, product, application, and region, providing detailed analysis and forecasts.
Exton-Based West Pharmaceutical Reports Higher Q4 Sales, Earnings
West Pharmaceutical Services Inc. (NYSE: WST) reported strong financial results for Q4 2025 and the full year, with increased net sales and adjusted diluted earnings per share. The company's Proprietary Products segment, particularly High-Value Product Components, drove growth. West Pharmaceutical anticipates continued positive momentum and sustainable growth in 2026, forecasting higher net sales and adjusted diluted EPS.
5 Thought-Provoking Analyst Inquiries from West Pharmaceutical Services’ Fourth Quarter Earnings Discussion
West Pharmaceutical Services reported strong Q4 results, exceeding analyst expectations in revenue, EPS, and EBITDA, driven by high-value product demand, particularly for biologic drugs and GLP-1 therapies. The company's profitability benefited from a favorable product mix and increased capacity. Analysts' questions during the earnings call focused on GLP-1 outlook, supply chain, new manufacturing facilities, and factors driving margin improvement, with management providing insights into capacity expansion and stable pricing for new molecules.
5 Insightful Analyst Questions From West Pharmaceutical Services's Q4 Earnings Call
West Pharmaceutical Services reported robust Q4 2025 results, driven by high-value product components for biologics and GLP-1 therapies, exceeding analyst revenue and EPS estimates. The article highlights five key analyst questions from the earnings call, covering topics such as GLP-1 guidance conservatism, capacity constraints, new GLP-1 molecule component needs, manufacturing site ramp-up, and margin expansion drivers. Future catalysts include regulatory conversions, capacity ramp-up, and expansion of biologics and GLP-1 pipelines.
5 Insightful Analyst Questions From West Pharmaceutical Services’s Q4 Earnings Call
West Pharmaceutical Services reported strong Q4 CY2025 results, exceeding analyst expectations for revenue, EPS, and EBITDA, driven by high-value products in biologics and GLP-1 therapies. Management emphasized continued investments in manufacturing capacity, particularly in Europe, to meet surging demand. Key analyst questions focused on the conservatism of GLP-1 guidance, capacity constraints outside GLP-1, specific needs for new GLP-1 molecules, the ramp-up of new manufacturing sites, and drivers for margin expansion.
Assessing West Pharmaceutical Services (WST) Valuation After Earnings Beat Guidance And US$1b Buyback Announcement
West Pharmaceutical Services (WST) reported strong Q4 and full-year 2025 results, exceeding expectations and announcing a new US$1 billion share repurchase program. Despite a recent cooling in share price momentum, the stock appears undervalued according to a narrative fair value model, yet its P/E ratio suggests some valuation risk. Investors are prompted to consider these mixed signals and explore further analyses to make informed decisions.
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST)
Morgan Stanley analysts have issued new ratings on several healthcare companies. Terence Flynn maintained a Sell rating on Crispr Therapeutics AG (CRSP) with a $33.00 price target. Judah Frommer gave Galapagos (GLPG) a Sell rating and a $22.00 price target, while Kallum Titchmarsh maintained a Hold rating on West Pharmaceutical Services (WST) with a $285.00 price target.
5 Thought-Provoking Analyst Inquiries from West Pharmaceutical Services’ Fourth Quarter Earnings Discussion
West Pharmaceutical Services reported strong Q4 results, exceeding analyst expectations in revenue and EPS, driven by demand for high-value components for biologic and GLP-1 drugs. The article highlights key analyst questions from the earnings call, addressing topics like GLP-1 guidance caution, supply limitations, new GLP-1 molecule requirements, manufacturing facility progress, and drivers of margin improvement. The company's strategic focus remains on expanding capacity and optimizing its product portfolio.
West Pharmaceutical Services (NYSE:WST) to Buyback $1.00 billion in Outstanding Shares
West Pharmaceutical Services (NYSE:WST) has authorized a $1.00 billion stock repurchase program, indicating the company's belief that its stock is undervalued. This buyback plan allows for the acquisition of up to 5.6% of outstanding shares. The announcement follows strong Q results, where WST exceeded EPS and revenue expectations, and provided encouraging FY2026 guidance.
West Pharmaceutical Services Maintains Quarterly Dividend, Authorizes $1 Billion Share Repurchase
West Pharmaceutical Services (WST) announced it is maintaining its regular quarterly dividend on common stock and has authorized a new $1 billion share repurchase program. The dividend will be payable on May 6, 2026. This news follows a series of analyst rating adjustments and the company's recent Q4 2025 earnings report, where it forecasted 2026 profit above estimates due to strong demand for drug components.
West Pharmaceutical Services, Inc. Declares Regular Quarterly Dividend on Common Stock, Payable on May 6, 2026
West Pharmaceutical Services, Inc. (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share on its common stock. This dividend is payable on May 6, 2026, to shareholders of record as of April 29, 2026. The announcement was made on February 16, 2026, by the company's Board of Directors.
West Pharmaceutical Declares Quarterly Dividend and Share Repurchase Program
West Pharmaceutical has declared a quarterly dividend of $0.22 per share, payable on May 6, 2026, and initiated a new share repurchase program of up to $1 billion in common stock. These actions reflect the company's commitment to shareholder returns and its flexible approach to capital management. Analysts have mixed views on the stock, with Deutsche Bank raising its price target while UBS lowered it, both maintaining a 'Buy' rating.
West Pharmaceutical clears $1B for stock buybacks and a May dividend
West Pharmaceutical Services (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share, payable on May 6, 2026. Additionally, the company's board has authorized a new $1.0 billion share repurchase program with no expiration date, following the full utilization of its previous program. These actions highlight West's ongoing commitment to returning capital to shareholders through both dividends and buybacks.
West Announces Quarterly Dividend and Share Repurchase Program
West Pharmaceutical Services, Inc. (NYSE: WST) has announced a regular quarterly dividend of $0.22 per share, payable on May 6, 2026, to shareholders of record on April 29, 2026. Additionally, the Board of Directors authorized a new share repurchase program of up to $1 billion of the Company's common stock, following the full utilization of its previous program. West, a global leader in injectable drug administration solutions, generated $3.07 billion in net sales in fiscal year 2025.
How West Pharmaceutical Services Inc. (WST) Affects Rotational Strategy Timing
This article analyzes West Pharmaceutical Services Inc. (WST) for rotational strategy timing, indicating neutral near and mid-term readings but a strong long-term positive bias. It highlights an exceptional risk-reward setup targeting a 10.6% gain and presents three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Charles River Laboratories (CRL) is set to report its Q4 earnings on Wednesday. Analysts anticipate a 2.2% year-on-year revenue decline to $980.9 million and adjusted earnings of $2.35 per share. Despite solid past performance in beating revenue estimates, the stock has underperformed its peers recently, and ongoing economic uncertainties have impacted the broader drug development inputs & services segment.
West Pharmaceutical Services launches Synchrony S1 prefillable syringe system
West Pharmaceutical Services has introduced its new Synchrony S1 prefillable syringe (PFS) system, designed to accelerate drug development. The system aims to benefit pharmaceutical applications and more information can be found in a recent publication by Drug Development & Delivery.
Charles River Laboratories (CRL) Q4 Earnings: What To Expect
Charles River Laboratories (CRL) is set to report its Q4 earnings, with analysts expecting a 2.2% year-on-year revenue decline to $980.9 million and adjusted earnings of $2.35 per share. The company has generally beaten revenue estimates in the past, and analyst estimates have remained consistent. The broader drug development inputs & services segment has underperformed recently, with CRL's stock down 26.1% over the last month.
West Pharmaceutical Services (WST) Stock Analysis: A Look At Its 27% Potential Upside
West Pharmaceutical Services (WST) is presented as a compelling investment in the healthcare sector, showing strong financial health with a 7.50% revenue growth and an impressive 16.86% return on equity. Analysts are largely positive, with an average target price suggesting a 27.46% potential upside. The company's focus on innovative drug containment and delivery systems positions it as a key player in the medical instruments and supplies industry.
SHAREHOLDER INQUIRY: Halper Sadeh LLC Probes HFWA, FSFG, TIPT for Shareholder Interests
Halper Sadeh LLC is investigating Heritage Financial Corporation (HFWA), First Savings Financial Group (FSFG), and Tiptree Inc. (TIPT) for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions. The law firm is offering free consultations to shareholders concerned about their rights and options. This investigation comes amidst recent positive financial reports and dividend announcements from Heritage Financial Corporation, as well as analyst upgrades.
West Pharmaceutical Services, Inc. (NYSE:WST) Sees Significant Increase in Short Interest
Short interest in West Pharmaceutical Services (NYSE:WST) increased significantly by 33.4% as of January 30th, reaching 2,560,146 shares, representing about 3.6% of its shares sold short. This rise in bearish positioning occurred despite the company reporting a strong Q4 earnings beat and issuing bullish FY 2026 guidance, driven by robust demand for its High-Value Product (HVP) components and progress with its SmartDose system. Analysts currently hold a consensus "Buy" rating for WST with an average price target of $314.56.
Earnings Release: Here's Why Analysts Cut Their West Pharmaceutical Services, Inc. (NYSE:WST) Price Target To US$319
Analysts have cut the price target for West Pharmaceutical Services, Inc. (NYSE:WST) to US$319 despite the company's annual results being roughly in line with revenue and EPS estimates. While revenue growth is expected to accelerate slightly faster than historical rates, matching the wider industry, the consensus price target dropped by 6.3%. This suggests analysts were not entirely reassured by the latest results, leading to a lower future valuation estimate.
How Investors Are Reacting To West Pharmaceutical (WST) GLP-1 Momentum And Upbeat 2026 Sales Guidance
West Pharmaceutical Services (WST) reported a strong fourth quarter in 2025 with sales of US$805.0 million and issued optimistic guidance for 2026, projecting US$3.215–3.275 billion in net sales, driven by GLP-1 therapies and biologics. The company's investment narrative focuses on its role as a key supplier of high-value components and its strategic shift towards premium products. Despite upbeat guidance, investors are weighing the wide range of fair value estimates and the risks associated with product mix, pricing, and the SmartDose divestiture.
West Pharmaceutical’s Under-the-Radar Dividend Worth Watching
West Pharmaceutical Services (WST) offers a low-yielding but consistently growing dividend with a conservative 9% payout ratio, making it appealing for dividend growth investors. Despite a 2024 dip in free cash flow, largely due to increased capital expenditures for growth, the dividend remains well-covered, and the company's strong business fundamentals and raised guidance suggest a rebound. However, WST's capital allocation heavily favors share repurchases over significant dividend increases, and its stock has experienced recent volatility, indicating it's primarily a "growth over income" investment.
How Investors Are Reacting To West Pharmaceutical (WST) GLP-1 Momentum And Upbeat 2026 Sales Guidance
West Pharmaceutical Services reported strong Q4 2025 sales and issued an upbeat 2026 sales guidance, driven by momentum in GLP-1 therapies and biologics, alongside margin expansion. The company's investment narrative is centered on its role as a key supplier for GLP-1 components and its ability to shift towards premium products, despite the planned sale of its SmartDose 3.5ml platform to AbbVie. Investors are currently weighing the growth potential from GLP-1 demand against execution risks and valuation concerns, with fair value estimates showing a wide spread.
Cibc World Market Inc. Has $4.88 Million Holdings in West Pharmaceutical Services, Inc. $WST
Cibc World Market Inc. significantly increased its stake in West Pharmaceutical Services (NYSE:WST) by 300% in Q3, now holding 18,586 shares valued at approximately $4.88 million. This increased institutional interest follows West Pharmaceutical Services beating Q4 earnings and revenue estimates and providing strong FY2026 guidance. Analysts have reiterated "Buy" ratings and raised price targets for the stock, reflecting positive market sentiment stemming from robust demand for drug components and progress in proprietary products like SmartDose.
Caprock Group LLC Purchases New Shares in West Pharmaceutical Services, Inc. $WST
Caprock Group LLC has acquired a new position of 5,965 shares in West Pharmaceutical Services, Inc. (NYSE:WST) during the third quarter, valued at approximately $1,473,000. This comes as several institutional investors have adjusted their holdings in the medical instruments supplier. West Pharmaceutical Services recently reported strong Q4 earnings, beating analyst estimates, and provided positive FY 2026 guidance, leading to positive market sentiment and analyst support.
Stephens Cuts Price Target on West Pharmaceutical Services to $320 From $350, Maintains Overweight Rating
Stephens has lowered its price target for West Pharmaceutical Services (WST) to $320 from $350, while reaffirming an Overweight rating on the stock. This adjustment comes amidst other analyst revisions, including UBS setting a target of $340 and Barclays lowering theirs to $265, reflecting varying outlooks on the company's future performance. West Pharmaceutical Services recently reported its Q4 2025 earnings and provided a positive 2026 profit forecast, driven by strong demand for drug components.
Merit Medical Systems (MMSI) Stock Trades Up, Here Is Why
Shares of medical device company Merit Medical Systems (MMSI) rose by 3.6% following a softer-than-expected inflation report, which increased hopes for Federal Reserve interest rate cuts. The January Consumer Price Index (CPI) showed a smaller-than-forecast rise of 0.2%, with the annual rate cooling to 2.4%, suggesting potential monetary easing. This news, despite initial market volatility, was seen as significant by the market for MMSI, which had previously reported strong Q3 2025 financial results.
West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. reported solid Q4 2025 results, with revenues exceeding expectations and strong growth in high-value product components, driven by GLP-1 demand, Annex 1 upgrades, and biologics recovery. The company provided optimistic 2026 guidance, anticipating 5% to 7% organic revenue growth and double-digit EPS growth, while conservatively estimating GLP-1 growth. They also highlighted strategic investments in capacity, innovation with products like West Synchrony, and the long-term opportunities presented by biologics, Annex 1 regulations, and the expanding GLP-1 market.
West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives
West Pharmaceutical Services (WST) reported Q3 FY 2025 results with revenue of US$804.6 million and basic EPS of US$1.94, however, its net profit margin slipped to 16.3% from 17.4% a year earlier. This margin contraction and a 6% revenue growth, which trails the broader US market, are raising concerns, especially given the company's high P/E ratio of 35.6x compared to a DCF fair value of US$54.99, indicating that optimistic growth expectations are already priced in.
West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives
West Pharmaceutical Services (WST) reported its FY 2025 third-quarter results, showing a slip in net profit margins from 17.4% to 16.3% and 6% revenue growth, which trails the broader US market. Despite analyst consensus forecasting margin improvement and future revenue potential driven by GLP-1 and high-value product components, the company's P/E ratio of 35.6x is significantly higher than peers and its DCF fair value, raising concerns for cautious investors. The article highlights a tension between bullish growth narratives and current financial performance, noting that current figures challenge some market expectations.
West Pharma forecasts 2026 profit above estimates on strong demand for drug components
West Pharmaceutical has forecasted its annual profit for 2026 to be above Wall Street estimates, driven by a strong demand for its medical components used in diabetes and obesity treatments, particularly GLP-1 related drugs. Despite concerns about the growth of oral weight-loss medications, CEO Eric Green anticipates continued growth for both injectable and oral formats, including an incremental boost from upcoming generic GLP-1 launches in several countries. The company also surpassed its fourth-quarter expectations due to robust demand for its proprietary products.
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
West Pharmaceutical Services (WST) reported a 5.2% stock increase following strong 2025 results, with sales reaching US$3.07 billion and net income at US$493.7 million. The company issued encouraging 2026 guidance, expecting first-quarter net sales of US$770-$790 million and full-year sales of US$3.22-$3.28 billion, emphasizing organic net sales growth as a key driver. This updated outlook helps investors understand the impact of underlying demand and product mix on the company's financial performance.
West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS
West Pharmaceutical Services (NYSE:WST) reported strong Q4 earnings, beating analyst expectations with an adjusted EPS of $2.04 on revenues of $805 million. The company raised its FY 2026 guidance, projecting adjusted EPS of $7.85–$8.20 and 5–7% organic revenue growth, driven by high-value product components. Despite strong demand, the company faces near-term capacity constraints and operational disruptions, although the SmartDose 3.5 divestiture is expected to be margin-positive.
West Pharma forecasts 2026 profit above estimates on strong demand for drug components
West Pharmaceutical is forecasting its 2026 annual profit above Wall Street estimates due to high demand for its medical equipment used in diabetes and obesity treatments. Despite concerns about competing oral weight-loss drugs impacting injectables, the company expects continued growth in both formats and projects incremental business from upcoming GLP-1 generics. The company also surpassed fourth-quarter expectations, reporting strong demand for its proprietary products.
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
West Pharmaceutical Services (WST) reported a strong fourth quarter and full-year 2025, with earnings and sales surpassing analyst expectations. The company also announced plans to sell its SmartDose 3.5ml product to AbbVie by mid-2026 and provided optimistic guidance for 2026, driven by robust performance in its Proprietary Products segment and HVP growth. The stock rose following the announcement, reflecting investor confidence in its strategic execution and future outlook.
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
West Pharmaceutical Services (WST) reported strong 2025 results, with sales reaching US$3.07 billion and net income at US$493.7 million. The company also issued a positive 2026 outlook, projecting first-quarter net sales of US$770-US$790 million and full-year sales of US$3.22-US$3.28 billion, emphasizing strong organic growth driven by underlying demand and product mix. This guidance reinforces the company's investment narrative, focusing on sustained demand for its high-value injectable components and delivery systems.
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations
West Pharmaceutical Services (WST) reported stronger-than-expected Q4 2025 earnings, with EPS of $2.04 against a forecast of $1.84, and revenue of $805 million, surpassing the projected $796.25 million. The company's stock rose 4.07% pre-market following the announcement. Key drivers of growth included high-value product components, expansion in the GLP-1 market, and investments in innovation and capacity, leading to a positive outlook for 2026 with projected revenue between $3.215 billion and $3.275 billion.
West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance
West Pharmaceutical Services (NYSE:WST) has issued its FY 2026 earnings guidance, projecting EPS between $7.85 and $8.20 and revenue between $3.2 billion and $3.3 billion, with EPS slightly above and revenue in line with analyst consensus. The company also reported a beats on Q4 2025 earnings and revenue, with an EPS of $2.04 against an expected $1.83, and revenue of $805 million against an expected $795.7 million. Analysts maintain a "Buy" rating for WST with a consensus price target of $326.22, and institutional ownership stands at approximately 93.9%.
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations
West Pharmaceutical Services (WST) reported strong Q4 2025 earnings, exceeding revenue and EPS expectations. The company posted an EPS of $2.04 against a forecast of $1.84, and revenue of $805 million compared to an anticipated $796.25 million, leading to a 4.07% rise in pre-market stock price. Key drivers include high-value product components, expansion in the GLP-1 market, and upgrades related to Annex 1 regulations.
West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars
West Pharmaceutical Services (NYSE:WST) reported strong Q4 CY2025 results, beating Wall Street's revenue and adjusted EPS expectations. The company achieved $805 million in revenue, a 7.5% year-on-year increase, and an adjusted EPS of $2.04, exceeding analyst estimates. Despite a decrease in operating margin, the company's free cash flow margin improved significantly, and its stock traded up 7.4% following the announcement.
Tandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. is scheduled to present company updates at three upcoming investor conferences in February and March 2026: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day, TD Cowen 46th Annual Health Care Conference, and Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The presentations will be webcast live and available for archive on the company's Investor Center website. Tandem Diabetes Care specializes in advanced automated insulin delivery systems like the Tandem Mobi system and the t:slim X2 insulin pump.
West Pharmaceutical Services Posts Solid Q4 and 2025 Results
West Pharmaceutical Services announced strong Q4 and full-year 2025 results, reporting a 7.5% year-over-year net sales increase in Q4 to $805.0 million and a 6.3% rise for the full year to $3.074 billion. The growth was primarily driven by High-Value Product Components, and the company issued optimistic 2026 guidance with projected mid-single-digit organic sales growth. While analysts rate WST stock as a Buy, TipRanks' AI Analyst, Spark, assigns a Neutral rating due to high valuation offsetting solid financial performance.
West Pharmaceutical Services (NYSE:WST) Beats Q4 Earnings Estimates, Shares Surge
West Pharmaceutical Services (NYSE:WST) surpassed Wall Street's expectations for its fourth-quarter earnings and revenue, driven by strong performance in its high-value product components. The company reported non-GAAP EPS of $2.04 against an estimated $1.85, and revenue of $805.0 million compared to an estimated $802.3 million. Following this positive news, shares of WST surged over 6% in pre-market trading, and the company also issued financial guidance for fiscal year 2026.
